2022
DOI: 10.1016/j.lungcan.2022.05.017
|View full text |Cite
|
Sign up to set email alerts
|

Current state and upcoming opportunities for immunoPET biomarkers in lung cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
4
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
3
1

Relationship

2
6

Authors

Journals

citations
Cited by 10 publications
(5 citation statements)
references
References 73 publications
0
4
0
1
Order By: Relevance
“…The figure illustrates the diversity of compound entities applied for different targets as well as the most advanced PET tracers undergoing clinical development. For more details see the articles of Swenck et al ( 13 ) and Slebe et al ( 14 ).…”
Section: The Tumor Microenvironment (Tme)mentioning
confidence: 99%
See 2 more Smart Citations
“…The figure illustrates the diversity of compound entities applied for different targets as well as the most advanced PET tracers undergoing clinical development. For more details see the articles of Swenck et al ( 13 ) and Slebe et al ( 14 ).…”
Section: The Tumor Microenvironment (Tme)mentioning
confidence: 99%
“…Many PET ligands ranging in size from 11 C- or 18 F-labeled small molecules to 89 Zr-labeled therapeutic antibodies targeting molecular features of the TME have been described ( Figures 2 , 3 ) ( 13 , 14 , 25 27 ). They provide impressive insights into TME’s enabling assessment of intralesional heterogeneity as well as of the tumor lesion heterogeneity within and between patients and its modulation caused by a pharmacological intervention ( 17 , 28 30 ).…”
Section: The Tumor Microenvironment (Tme)mentioning
confidence: 99%
See 1 more Smart Citation
“…Therapeutic radiopharmaceuticals прочности связывания с мишенью и функциональных свойств клеток-мишеней [53,54]. 18 F -изотоп, который чаще других применяется для проведения ПЭТ-исследований.…”
Section: терапевтические радиофармпрепаратыunclassified
“…Positron emission tomography (PET) enables assessment of molecular processes in vivo, and does not suffer from these drawbacks. Various PET tracers have been explored for their ability to visualize TME processes, and to study IO treatment effects [5]. A new PET tracer, 2'-deoxy-2'-[ 18 F] uoro-9-β-D-Arabinofuranosyl-guanine ([ 18 F]F-AraG), an analogue of AraG, the active substance of the drug Nelarabine, has been developed to image activated T-cells [6,7].…”
Section: Introductionmentioning
confidence: 99%